Document:

EX-10.3

 Exhibit 10.3 
 FINAL 
 20 September 2012 
 Siemens Healthcare Diagnostics Inc. 
 511 Benedict Avenue 

Tarrytown, NY 10591 
 USA 

 

	Re:	Supplemental Agreement – Reader Product Support Obligations and Responsibilities 

 Ladies and Gentlemen: 
 We refer to the Collaboration Agreement between Universal Biosensors Pty
Ltd. (“UBI”) and Siemens Healthcare Diagnostics Inc. (“Siemens”) dated September 9, 2011 (the “Collaboration Agreement”). Capitalized terms used but not otherwise defined
herein shall have the meanings provided in the Collaboration Agreement; provided, however, that the terms “Product” and “PT/INR Product” shall have the meanings provided in the Supply Agreement. 

By way of background: 
  

	 	•	 	 The Collaboration Agreement does not address the parties’ post-development and post-launch support obligations with respect to Reader Products,
and the Supply Agreement currently under negotiation between the parties for the supply of strip Products would not be an appropriate document in which to address such obligations because it does not address Reader Products.

  

	 	•	 	 The Requirements with respect to the Critical Care Reader include the use of *[REDACTED]. 

 

	 	•	 	 After completion of the Development Work for the Reader Products, Siemens will be free to arrange for manufacture of the Reader Products by a Third
Party of Siemens’ choosing (the “Manufacturer”) and to make modifications to the designs of the Reader Products and to modify and create derivative works of the UBI Collaboration Software incorporated in Reader Products.

  

	 	•	 	 Although UBI is willing to provide “fourth level support” (defined below) for Reader Products, UBI may not be able to provide such support
with respect to Siemens-modified wireless technology and Reader Products, including, without limitation, Reader Products incorporating Siemens’ modifications or derivative works of UBI Collaboration Software. 

In consideration of the foregoing premises and the mutual covenants contained in this letter agreement (the “Supplemental
Agreement”), UBI and Siemens, intending to be legally bound, hereby agree as follows: 
 1.    Critical Care
Reader Amended Requirements. As reimbursement to UBI for additional development work for the Critical Care Reader including creation of a base unit (being 
  

* Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  
 Page 2 of 19 

 

 
developed under the UBI Project referred to by the parties as “Rubix”) as set forth in Annex I and certain form factor changes to the Rubix base unit as set forth in
Annex II, Siemens shall pay to UBI a total of US$1.7 million, which shall be payable in three installments on the schedule set forth below: 
 (a) US$700,000 shall be paid by October 30, 2012; 
 (b)
US$500,000 shall be paid no later than April 30, 2013; provided that if UBI has not delivered an EP1 prototype of base unit and analyzer to Siemens and submitted the R3 (Siemens PDP) documentation UBI deliverables to Siemens by
April 30, 2013, then such amount shall be paid as promptly as practicable, and in any event within 30 days, after UBI has delivered such prototype and submitted such deliverables to Siemens; and 

(c) US$500,000 shall be paid no later than November 30, 2013; provided that if UBI has not provided the design documentation
required for manufacture of the PPU prototype base unit and analyzer to the Manufacturer by November 30, 2013, then such amount shall be paid as promptly as practicable, and in any event within 30 days, after UBI has provided such design
documentation to the Manufacturer. 
 For the avoidance of doubt, the amounts payable pursuant to this paragraph 1 are in addition to the
amounts payable by Siemens to UBI under the Collaboration Agreement with respect to Reader Product Development Work. All additional development work shall be conducted in accordance with and shall be subject to the terms of the Collaboration
Agreement and shall be considered Development Work thereunder. For the avoidance of doubt, references to Reader Product shall now be understood to also include the base unit. 
 It is understood by the parties that the Requirements, Development Plan, and the additional development work of Annexes I and II hereunder are only high level descriptions and continue to require
design choices and additional detail to determine how the high level requirement or specification will be met in practice. All such design choices and detail that are consistent with the high level descriptions are covered under the payments of the
Collaboration Agreement or this Supplemental Agreement and Siemens shall not be responsible for any further development cost with respect to design choices and detail consistent with such high level descriptions. To the extent Siemens requests a
change of the high level descriptions, Siemens will compensate UBI at UBI’s fully-burdened cost of implementing said change. 
  

	2.	Reader Product Support. 

(a) Technical Support and Training. UBI shall provide reasonable technical Reader Product support and training for Siemens
technical support, as contemplated by the Collaboration Agreement, and as further detailed in Annex III; provided, however, that: 
 (i) Siemens shall be solely responsible for providing technical support and training for Siemens technical support with respect to any change to *[REDACTED] not made by UBI or its
subcontractors incorporated in any Reader Product; and 
 (ii) Siemens acknowledges that any modification not made by UBI
or its subcontractors to the design of a Reader Product following completion of UBI’s Development Work on that Reader Product (“Design Modification”) or modification to or derivative work of 

 
 * Confidential portion has been omitted and has been filed separately with
the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 Page 3 of 19 

 

 UBI Collaboration Software not made by UBI or its subcontractors following completion of UBI’s
Development Work (“Software Modification”) may limit or prevent UBI from providing effective technical support and training for Siemens technical support, and Siemens therefore agrees that after reasonable efforts by UBI to
provide support and training the inability of UBI to provide such support and training for Reader Products with Design Modifications and/or Software Modifications shall not be deemed a breach by UBI of the Collaboration Agreement or this
Supplemental Agreement. 
 Subject to the foregoing limitations, to the extent such support is provided on-site at UBI’s
facilities, such support will be provided *[REDACTED]. In case Siemens needs on-site support at Siemens’ facilities, UBI shall send, upon Siemens’ reasonable request and *[REDACTED], a qualified person to Siemens’
facilities, at reasonable times and for a reasonable duration, in order to assist with the foregoing activities. 
 (b)
Siemens Customer Support. The parties acknowledge and agree that Siemens shall be solely responsible for interacting with customers. Siemens shall provide prompt and proficient first, second and third level support (as described below and in
Annex III attached hereto) for Reader Products and shall handle all customer complaints and inquiries in a professional and workmanlike manner at the cost of Siemens. For purposes of this paragraph 2(b), “first level
support” shall consist of first line phone support and standard troubleshooting techniques by Siemens; “second level support” shall consist of an elevated level of support over and above first level support and shall
include both internal team assignment and on-site troubleshooting by Siemens; and “third level support” shall consist of an elevated level of support beyond second level support and shall include Siemens assigning the matter to one
of its regional subject matter experts and/or the Manufacturer regarding the problem at issue and onsite trouble-shooting by Siemens. 
 (c) UBI Customer Support. In the event neither Siemens experts nor the Manufacturer can resolve a Reader Product service matter and escalation beyond third level support is required, UBI shall
advise and consult with Siemens regarding such matter (“fourth level support”) and shall investigate and respond to any such escalated service call from Siemens in accordance with Annex III; provided, however,
that: 
 (i) UBI shall apply reasonable efforts but will not be obligated to resolve fourth level support issues with
respect to * [REDACTED]; 
 (ii) Siemens acknowledges that a Design Modification or Software Modification to
a Reader Product may limit or prevent UBI from providing effective fourth level support for such Reader Product, and Siemens therefore agrees that the inability of UBI to provide effective fourth level support for Reader Products with Design
Modifications and/or Software Modifications shall not be deemed a breach by UBI of the Collaboration Agreement or this Supplemental Agreement; and 
 (iii) because UBI will not be the manufacturer or supplier of Reader Products or components thereof, there will exist fourth level support activities for which the Manufacturer, and not UBI, will
be responsible for resolving; however, UBI agrees to cooperate and provide reasonable assistance, support, and advice in working with Siemens and the Manufacturer to investigate and resolve any escalated matter even if the ultimate responsibility
lies with the Manufacturer. 
  
 * Confidential portion has been
omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 Page 4 of 19 

 

 Fourth level support by UBI may include root cause investigation and testing, but Siemens
shall be responsible for conducting any appropriate confirmatory testing in accordance with Siemens’ Quality Management System. Siemens shall escalate all events deemed as potential Medical Device Reportables (“pMDRs”)
to the appropriate regulatory affairs personnel of Siemens. Siemens shall be responsible for filing all Medical Device Reportables (“MDRs”) with the appropriate regulatory agencies and will inform UBI of such filings. Subject
to clauses (i), (ii) and (iii) of this paragraph 2(c), if an escalated matter is not responded to timely or is not closed out in accordance with Annex III by UBI, then upon written request of Siemens the parties shall
meet within *[REDACTED] of said request or as otherwise mutually agreed to by the parties to review the issue and create a plan to bring it to resolution. The parties shall also review and improve the escalation procedure to ensure that
properly escalated matters are responded to and closed timely. 
 (d) UBI Defect Correction. During the *[REDACTED]
period beginning upon initiation of the Siemens Full Commercialization Phase M300, as defined in the Siemens Product Development Process Handbook, Version 2 (the “Siemens Commercialization Phase”), for each
Reader Product or during the *[REDACTED] period beginning upon Siemens Commercialization Phase of a new strip Product other than the PT/INR Product *[REDACTED] for a Reader Product or a release of a new version of UBI Collaboration
Software developed by UBI or its subcontractor (the “Defect Correction Period”), UBI shall, * [REDACTED], correct defects in such Reader Product design or UBI Collaboration Software that prevent or materially
limit the usage or any of the functionality of the Reader Product as defined in the Functional Specification for the Reader Product (“Material Defects”), unless Design Modifications have been made to such Reader Product or
Software Modifications have been made by a party other than UBI or its subcontractor. UBI shall commence remedying any such Material Defect promptly after receipt of notification of such Material Defect and provide Siemens with a remedy as promptly
as practicable. 
 (e) Required Changes. If, as a condition to granting 510(k) clearance for (A) the first version
of each Reader Product for which Siemens submits a 510(k), or (B) a new strip Product other than the PT/INR Product *[REDACTED] in combination with a Reader Product for which Siemens submits a 510(k), the FDA requires changes to such
Reader Product or the UBI Collaboration Software incorporated therein, then UBI, in consultation with Siemens, shall make the required changes *[REDACTED]. In addition, in the event of: 

(i) a Recall (as defined in the Supply Agreement) of a strip Product, the costs of which Recall are either *[REDACTED] that
necessitates a change to such Product; or 
 (ii) a Major Change (as defined in the Supply Agreement) to a strip Product
within the scope of clause (i) or clause (ii) of Section 3.7(a) of the Supply Agreement; 
 that, in each case, the parties
mutually agree in writing necessitates a change to a Reader Product or UBI Collaboration Software, the required change to the Reader Product or UBI Collaboration Software shall be made by UBI without further compensation from Siemens. 

(f) UBI Design Change Support. From and after initiation of the Siemens Commercialization Phase for each Reader Product, upon
Siemens’ request and as specified by Siemens, UBI agrees to make, test and release changes to the Reader Product design or UBI Collaboration Software and to provide reasonable assistance to Siemens with Design Modifications and/or Software
Modifications, in each case, on a fee-for-service basis at *[REDACTED] of UBI’s fully-burdened cost, and on other commercially reasonable terms to be negotiated in good faith by the parties. 

 
 * Confidential portion has been omitted and has been filed separately with
the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 Page 5 of 19 

 

 Notwithstanding any provision of the Collaboration Agreement to the contrary, this
paragraph 2 of this Supplemental Agreement sets forth the entire liability of UBI under the Collaboration Agreement with respect to each Reader Product from and after initiation of the Siemens Commercialization Phase for such Reader Product.

 3.    Reader Product Recall. In the event that any Reader Product non-conformity or governmental authority
requires, or Siemens or any of its Affiliates or licensees voluntarily conducts, any Reader Product recall, destruction, withholding from the market, or field corrective action (in each case, a “Recall”), Siemens shall be
solely responsible for conducting such Recall, for making all filings, submissions and communications with regulatory agencies in connection with such Recall, and for all customer communications regarding such Recall, all at Siemens’ sole cost
and expense. 
 4.    Miscellaneous. This Supplemental Agreement, including Annexes I, II and III hereto,
together with the Collaboration Agreement (as supplemented and amended by this Supplemental Agreement), is both a final expression of the parties’ agreement with respect to Reader Products and a complete and exclusive statement with respect to
all terms relating to Reader Products. In the event of any conflict between the provisions of this Supplemental Agreement and Annexes I, II and III hereto, the provisions of this Supplemental Agreement shall control. This Supplemental Agreement
may only be amended, modified or supplemented in a writing expressly stated for such purpose and signed by the parties to this Supplemental Agreement. This Supplemental Agreement may be assigned by a party only in conjunction with a permitted
assignment by such party of the Collaboration Agreement. This Supplemental Agreement may be executed in counterparts, including by transmission of facsimile or PDF copies of signature pages to the parties or their representative legal counsel, each
of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. 

  
 Page 6 of 19 

 

 If the foregoing is acceptable to you, please sign this Supplemental Agreement in the space provided below
and return it to me. 
  

	
	 Sincerely,
  
 UNIVERSAL BIOSENSORS PTY LTD.

	
	/s/ PAUL WRIGHT
	 Paul Wright
 Chief Executive
Officer

  

			
	 Agreed to and accepted as of the Effective Date:

 
 SIEMENS HEALTHCARE DIAGNOSTICS
INC.

		
	By:	 	/s/ DAVID
STEIN                         9/19/12
	Name:	 	David Stein
	Title:	 	CEO POC
		
	By:	 	/s/ WOLFGANG WRUMNIG     9/18/12
	Name:	 	Wolfgang Wrumnig
	Title:	 	CFO

  

					
	

	  	 	Page 7 of 19	  

  

 Annex I 
 Rubix Base Unit Description 
  

							
	 Project Name:
	  	Rubix	  			
			
	 Document Title:
	  	Rubix Base Unit Form Factor	  			
			
	Prepared By:	  	Michael Parker	  	 	19-July-2012	  

  
  

 

					
	 Approvals

	 	 	 
	 Signature
	 	Organization Responsibility	 	Date
	 	 	 
	 	 	 Engineering, Siemens

Michael Parker
	 	 
	 	 	 
	 	 	 Project Manager, Siemens

Raimund Bronold
	 	 
	 	 	 
	 	 	 Project Manager – UBI

Guido Brandt
	 	 
	 	 	 
	 	 	 Marketing, Siemens

Arnol Rios
	 	 
	 	 	 
	 	 	 UXD, Siemens

Jeff Morang
	 	 

  

					
	

	  	 	Page 8 of 19	  

  

 *[REDACTED] 

  

					
	

	  	 	Page 9 of 19	  

  

 Annex II 
 Rubix Form Factor Changes 
 *[REDACTED] 

 
 * Confidential portion has been omitted and has been filed separately with
the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  

					
	

	  	 	Page 10 of 19	  

  

 Annex III 
 Service and Support Escalation Levels Defined 
 This Annex III applies solely to
Reader Products and is subject in all respects to the terms of the Supplemental Agreement to which it is attached. For clarification, UBI will not be manufacturing or supplying Reader Products or components thereof. Accordingly, references to
“Supplier” herein do not necessarily refer to UBI and not all fourth level support activities identified in this Annex III will be the responsibility of UBI. 

 
 

 
 *[REDACTED] 
  

* Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  

					
	

	  	 	Page 11 of 19	  

  

 Priority 1 – an escalation or complaint where the customer’s use of the
product is significantly restricted, there is a major system impact, and there is no acceptable workaround, or involve adverse incidents that meet the definition of a pMDR/MDVR. 

Examples: 

Affecting the operation of the service and the system/product: 

 

	 	•	 	 A total failure of the system/product which results in the loss of producing viable patient results. 

	 	•	 	 Loss of system/product capability based on measurable configurations. (parameter failures, error messages, discordant results, etc,)

	 	•	 	 System reboot during routine system operation. 

	 	•	 	 Safety relevant event at customer site. 

  

	 	•	 	 Total system or network crash. 

	 	•	 	 Virus attacks on systems. 

 Priority 2 – an escalation or complaint where the customer is able to perform their daily workload, however, the use of documented service and troubleshooting procedures and/or workarounds has
not been able to restore full functionality. The customer is willing to perform the workaround for only a limited period of time and is pressing for a rapid resolution. 
 Examples: 
 Affecting the service and or routine operation of the system/product:

  

	 	•	 	 Loss of features and some functionality 

	 	•	 	 Customer system has a partial failure or there is a temporary (sporadic) problem. 

	 	•	 	 Short breaks in operation of the system or subsystem, 

 Priority 3 – an escalation or complaint where the customer is able to perform their daily workload, however, the product is not meeting performance claims as documented in labeled
documentation. The customer has accepted our workaround and is willing to perform the workaround for and extended period of time. 
  

	 	•	 	 Faults solved with a workaround. 

	 	•	 	 Sporadic HW/SW/Assay issues not impairing patient results or having an effect on laboratory operations. 

  

					
	

	  	 	Page 12 of 19	  

  

 *[REDACTED] 
  

* Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  

					
	

	  	 	Page 13 of 19	  

  

 Product Health Team (PHT): Siemens Healthcare Diagnostics and UBI 

*[REDACTED] 
  
 * Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.Second Amendment to Third Amended and Restated Rights Agreement

 Exhibit 4.1 
 EXECUTION VERSION 
 SECOND AMENDMENT TO
THIRD AMENDED AND RESTATED RIGHTS AGREEMENT 
 This Second Amendment to Third Amended and Restated Rights Agreement (the
“Amendment”) by and between Harvest Natural Resources, Inc., a Delaware corporation (the “Company”), and Wells Fargo Bank, N.A., a California corporation (the “Rights Agent”), is made and entered into as of
February 1, 2013. 
 RECITALS 
 WHEREAS, the Company and the Rights Agent are parties to the Third Amended and Restated Rights Agreement, dated as of August 23, 2007, as amended by the Amendment to Third Amended and Restated Rights
Agreement, dated as of October 28, 2010 (as so amended, restated and further amended, the “Rights Agreement”); and 
 WHEREAS, the Company wishes to amend the Rights Agreement in certain respects regarding the beneficial ownership of Common Shares of the Company by MSD Capital, L.P. and its Affiliates and Associates and
the status of MSD Capital, L.P. and its Affiliates and Associates as an “Acquiring Person”, as such term is defined in the Rights Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the parties hereto hereby agree as follows: 

1. Section 1(a) of the Rights Agreement. 
 (a) Section 1(a) of the Rights Agreement is hereby amended and restated to provide in its entirety as follows: 
 “(a) A Person shall be deemed an “Acquiring Person” as set forth in subsections (i), (ii) and (iii) below: 

(i) Except as otherwise provided in subsection 1(a)(ii) or (iii) below, “Acquiring Person” shall mean any Person (as such
term is hereinafter defined) who or which, together with all Affiliates and Associates (as such terms are hereinafter defined) of such Person, shall be the Beneficial Owner (as such term is hereinafter defined) of 15% or more of the Common Shares
then outstanding, but shall not include the Company, any Subsidiary (as such term is hereinafter defined) of the Company, any employee benefit plan of the Company or any Subsidiary of the Company, or any entity holding Common Shares for or pursuant
to the terms of any such plan. 
 (ii) Notwithstanding the foregoing, except as set forth in subsection 1(a)(iii) below, no
Person shall be deemed to be an Acquiring Person either (A) as the result of an acquisition of Common Shares by the Company which, by reducing the number of Common Shares outstanding, increases the proportionate number of Common Shares owned by
such Person to 15% or more of the Common Shares of the Company then outstanding; provided, however, that if a Person shall become the Beneficial Owner of 15% or more of the Common Shares then 

  
 1 

 
outstanding by reason of share purchases by the Company and shall, after such share purchases by the Company, become the Beneficial Owner of any additional Common Shares of the Company, then such
Person shall be deemed to be an Acquiring Person, (B) if within five Business Days (as such term is hereinafter defined) after such Person would otherwise have become an Acquiring Person (but for the operation of this clause (B)), such Person
notifies the Board of Directors of the Company that such Person did so and within two Business Days after such notification such Person is the Beneficial Owner of less than 15% of the outstanding Common Shares of the Company, or (C) if within
ten Business Days (as such term is hereinafter defined) after the Company learns that such Person would otherwise have become an Acquiring Person (but for the operation of this clause (C)), the Company’s Board of Directors determines, by duly
adopted resolution, that such Person should not be deemed an Acquiring Person and adopts and approves a supplement to this Agreement pursuant to Section 27 exempting such Person from being deemed an Acquiring Person, with such conditions, if
any, that the Board of Directors deems appropriate. 
 (iii) Notwithstanding the foregoing subsections 1(a)(i) and (ii), MSD
Capital, L.P. (“MSD”), MSDC Management, L.P. (“MSDC”) and their respective Affiliates and Associates (as such terms are hereinafter defined), shall not be deemed to be an Acquiring Person as long as MSD, MSDC and their respective
Affiliates and Associates, shall be the Beneficial Owner of less than 15% of the Common Shares outstanding; provided, however, that MSD, MSDC and their respective Affiliates and Associates, shall not be deemed to be an Acquiring Person as the result
of (A) any acquisition of Common Shares by the Company which, by reducing the number of Common Shares outstanding, increases proportionate number of Common Shares owned by MSD, MSDC and their respective Affiliates and Associates, to 15% or
more, (B) any anti-dilution or other adjustments to any convertible securities (including convertible notes and warrants) held by MSD, MSDC or their respective Affiliates and Associates which increase the proportionate number of Common Shares
owned by MSD, MSDC and their respective Affiliates and Associates, to 15% or more and (C) MSD, MSDC or their respective Affiliates and Associates inadvertently becoming an Acquiring Person as the result of the acquisition of additional Common
Shares and such party or parties so notify the Board of Directors of the Company within five business days and within two business days after such notice divests itself of such additional Common Shares.” 

2. Other Terms of the Rights Agreement. Except as otherwise provided in this Amendment, all other terms of the Rights Agreement
shall remain in full force and effect. All references in the Rights Agreement to “this Agreement” shall be read as references to the Rights Agreement, as amended by this Amendment, but references to the date of the Rights Agreement shall
remain references to August 23, 2007. 
 3. Counterparts. This Amendment may be executed by the parties hereto in
separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies hereof each signed by less
than all, but together signed by all of the parties hereto. 
 4 Choice of Law. The parties intend that the laws of the
State of Delaware shall govern the validity of this Amendment, the construction of its terms and the interpretation of the rights and duties of the parties hereto, without regard to conflict of laws provisions. 

(The remainder of this page intentionally left blank.) 

  
 2 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of February 1, 2013.

  

									
		 		 		 	HARVEST NATURAL RESOURCES, INC.
	Attest:	 		 		 		 	
					
	By:	 	 /s/ Keith L. Head
	 		 	By:	 	 /s/ James A. Edmiston

	Name:	 	Keith L. Head	 		 	Name:	 	James A. Edmiston
	Title:	 	Vice President and General Counsel	 		 	Title:	 	President and Chief Executive Officer
				
		 		 		 	WELLS FARGO BANK, N.A.
	Attest:	 		 		 		 	
					
	By:	 	 /s/ Steven J. Hoffman
	 		 	By:	 	 /s/ Martin J. Knapp

	Name:	 	Steven J. Hoffman	 		 	Name:	 	Martin J. Knapp
	Title:	 	Vice President	 		 	Title:	 	Assistant Vice President

 (Signature page to Second Amendment to Third Amended and Restated Rights Agreement)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]